PolyPeptide Group AG (SWX:PPGN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
16.56
-0.28 (-1.66%)
Apr 3, 2025, 1:54 PM CET
-45.35%
Market Cap 541.80M
Revenue (ttm) 315.97M
Net Income (ttm) -18.35M
Shares Out 33.00M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,303
Average Volume 96,669
Open 16.56
Previous Close 16.84
Day's Range 16.44 - 16.94
52-Week Range 15.26 - 35.80
Beta 1.00
RSI 33.91
Earnings Date Mar 11, 2025

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195... [Read more]

Sector Healthcare
Founded 1952
Employees 1,362
Stock Exchange SIX Swiss Exchange
Ticker Symbol PPGN
Full Company Profile

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR Financial Statements

News

There is no news available yet.